Selective Degradation and Inhibition of SARS-CoV-2 3CLpro by MMP14 Reveals a Novel Strategy for COVID-19 Therapeutics
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26199401 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Hyun Lee und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Science, College of Pharmacy & Biophysics Core, the Research Resource Center, University of Illinois Chicago, Chicago, I…. Hauptthemen laut MEDLINE: Coronavirus 3C Proteases, Matrix Metalloproteinase 14, Cysteine Endopeptidases, Viral Nonstructural Proteins. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NEI NIH HHS, NIAID NIH HHS, NIH HHS.
Abstract (Originalsprache)
Novel therapies to treat infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of respiratory coronavirus disease 2019 (COVID-19), would be of great clinical value to combat the current and future pandemics. Two viral proteases, papain-like protease (PLpro) and the main protease 3-chymotrypsin-like protease (3CLpro), are vital in processing the SARS-CoV-2 polyproteins (pp1a and pp1ab) and in releasing 16 nonstructural proteins, making them attractive antiviral drug targets. In this study, we investigated the degradation of the SARS-CoV-2 main protease 3CLpro by matrix metalloproteinase-14 (MMP14). MMP14 is known to recognize over 10 distinct substrate cleavage sequences. Through sequence analysis, we identified 17 and 10 putative MMP14 cleavage motifs within the SARS-CoV-2 3CLpro and PLpro proteases, respectively. Despite the presence of potential sites in both proteins, our in vitro proteolysis assays demonstrated that MMP14 selectively binds to and degrades 3CLpro, but not PLpro. This selective proteolysis by MMP14 results in the complete loss of 3CLpro enzymatic activity. In addition, SARS-CoV-2 pseudovirus replication was inhibited in 293 T cells when either full-length MMP14 or its catalytic domain (cat-MMP14) were overexpressed, presumably due to 3CLpro degradation by MMP14. Finally, to prevent MMP14 from degrading off-target proteins, we propose a new recombinant pro-PL-MMP14 construct that can be activated only by another SARS-CoV-2 protease, PLpro. These findings could open the potential of an alternative therapeutic strategy against SARS-CoV-2 infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Science, College of Pharmacy & Biophysics Core, the Research Resource Center, University of Illinois Chicago, Chicago, IL 60607, USA.
- Biophysics Core, the Research Resource Center, University of Illinois Chicago, Chicago, IL 60607, USA.
- Department of Ophthalmology and Visual Sciences, Illinois Eye and Ear Infirmary, College of Medicine, University of Illinois Chicago, Chicago, IL 60612, USA.
- Department of Microbiology and Immunology, College of Medicine, University of Illinois Chicago, Chicago, IL 60612, USA.
ORCID-Profile: Hyun Lee, Elizabeth J Mulder
Förderung
- NEI NIH HHS
- NIAID NIH HHS
- NIH HHS
- National Institutes of Health
- Eversight
Zitieren
APA
Lee, H., Hwang, Y., Mulder, E. J., Song, Y., Choi, C., Rong, L., Azar, D. T., & Han, K. Y. (2025). Selective Degradation and Inhibition of SARS-CoV-2 3CLpro by MMP14 Reveals a Novel Strategy for COVID-19 Therapeutics. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26199401
Vancouver
Lee H, Hwang Y, Mulder EJ, Song Y, Choi C, Rong L, et al. Selective Degradation and Inhibition of SARS-CoV-2 3CLpro by MMP14 Reveals a Novel Strategy for COVID-19 Therapeutics. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26199401
BibTeX
@article{Lee2025,
author = {Lee, Hyun and Hwang, Yunjeong and Mulder, Elizabeth J and Song, Yuri and Choi, Calista and Rong, Lijun and Azar, Dimitri T and Han, Kyu-Yeon},
title = {Selective Degradation and Inhibition of SARS-CoV-2 3CLpro by MMP14 Reveals a Novel Strategy for COVID-19 Therapeutics},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26199401}
}
EUVIMED